Alnylam Pharmaceuticals
ALNY
#868
Rank
S$37.51 B
Marketcap
S$280.39
Share price
1.43%
Change (1 day)
-49.84%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of August 2026 (TTM): 6.84

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 27.3. At the end of 2026 the company had a P/S ratio of 9.82.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20269.82-31.03%
202514.24.27%
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Novartis
NVS
5.25-23.24%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
1.88-72.56%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
5.41-20.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.8115-88.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
1.76-74.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
2.38-65.28%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
19.8 190.10%๐Ÿ‡บ๐Ÿ‡ธ USA